Use of the PCSK9 inhibitor, evolocumab, in patients with heterozygous familial hypercholesterolemia
- MOJ Public Health
Evolocumab is a monoclonal immunoglobulin G2 that acts against human proprotein convertase subtilisin/kexin type 9 (PCK9) used against Homozygous familial hypercholesterolemia and Heterozygous familial hypercholesterolemia in high cardiovascular disease risk patients with increased level of triglycerides. Evolocumab is administered subcutaneously 420mg every month and 140 mg twice a week in patients with HeFH as evaluated by RUTHERFORD and RUTHERFORD 2 trials. This paper reviews the six clinical trials of evolocumab that evaluated the efficacy of the drug for heterogenous familial hypercholesterolemia.
evolocumab, screening, cholesterol, reduction, triglyceride, receptor, mutations, dosing, schedules, discontinuation, randomized, placebo, adverse events, primary, efficacy, atorvastatin